# ChargeForward ContinualFocus CForward CysticFibrosis

# ChargeForward ContinualFocus CForward CysticFibrosis

We are developing novel therapies to treat the cause of #CysticFibrosis to give every person with CF a long and healthy life.

OUR SCIENCE

What is cystic fibrosis?

Cystic fibrosis (CF) is a life-limiting, genetic disease that causes dysfunction across many organs, though the most life-limiting complication occurs in the lungs through repeated infectious respiratory exacerbations.

Patience stories and blog for Proteostasis_Therapeutics_Inc_biotech_company_cystic fibrosis

OUR SCIENCE

CFTR modulators and pipeline

Our goal is to develop drugs that restore CFTR activity and to provide more disease-modifying options for people with CF.

OUR SCIENCE

Available clinical trials

We are currently identifying eligible patients for our CHOICES trial through ex vivo screening of patient derived organoids and their responsiveness to our CFTR modulators. The clinical portion of the trial will initiate in the second half of 2020.

CF LIFE

It’s life CF. Because life comes first.

We know people with CF see life as more than a disease state and their accomplishments inspire us daily.

Patience stories and blog for Proteostasis_Therapeutics_Inc_biotech_company_cystic fibrosis

INVESTOR RELATIONS

Overview

View our investor overview or browse the investor relations section to view our financial information and press releases.

NASDAQ: PTI
$1.37
Change
-0.01 (-0.72%)
Volume
848412
Today’s Open
1.38
Previous Close
1.38
Today’s High
1.42
Today’s Low
1.33
52 Week High
4.72
52 Week Low
0.61

LOOKING TO GET INVOLVED OR HAVE A QUESTION? CONTACT US